PCWA
SYRE icon

Pacific Capital Wealth Advisors’s Spyre Therapeutics SYRE Stock Holding History

Pacific Capital Wealth Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8
Closed -$186 – 339
2024
Q4 		$186 Hold
8
– – ﹤0.01% 378
2024
Q3 		$235 Hold
8
– – ﹤0.01% 467
2024
Q2 		$188 Hold
8
– – ﹤0.01% 495
2024
Q1 		$303 Hold
8
– – ﹤0.01% 498
2023
Q4 		$172 Buy
+8
New +$110 ﹤0.01% 327

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pacific Capital Wealth Advisors's SYRE Position: Q1 2025 in Review

Pacific Capital Wealth Advisors sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 8 shares — an estimated $186 sold.

Pacific Capital Wealth Advisors first reported a position in SYRE in Q4 2023 and held it in 5 quarters. The position peaked at $303 in Q1 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Pacific Capital Wealth Advisors reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Pacific Capital Wealth Advisors sold 8 Spyre Therapeutics shares in Q1 2025, an estimated $186.
  • Pacific Capital Wealth Advisors first reported a position in Spyre Therapeutics in Q4 2023 and held it in 5 quarters.
  • Pacific Capital Wealth Advisors's Spyre Therapeutics position peaked at $303 in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Pacific Capital Wealth Advisors's 13F filing for Q1 2025, filed 18 Apr 2025.